These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26439891)

  • 21. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Extended release calcifediol and paricalcitol in the treatment of secondary hyperparathyroidism: a network meta-analysis of indirect comparison].
    Franchi M; Galassi A; Corrao G
    G Ital Nefrol; 2023 Feb; 40(1):. PubMed ID: 36883925
    [No Abstract]   [Full Text] [Related]  

  • 23. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
    Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
    Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
    Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Experience with active vitamin D metabolites in phosphorus-calcium metabolic disorders in patients with predialysis chronic kidney disease].
    Milovanova LIu; Dobrosmyslov IA; Milovanov IuS
    Ter Arkh; 2014; 86(6):52-6. PubMed ID: 25095656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.
    Kumar N; Lindberg J; David K; Morris J; Menoyo J
    Am J Nephrol; 2009; 29(2):71-8. PubMed ID: 18689981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
    Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
    Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
    Sprague SM; Coyne D
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D resistance in chronic kidney disease (CKD).
    Parikh A; Chase HS; Vernocchi L; Stern L
    BMC Nephrol; 2014 Mar; 15():47. PubMed ID: 24641586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy.
    Gesek FA; Desmond JS
    Nephrol Nurs J; 2008; 35(2 Suppl):5S-22S; quiz 23S. PubMed ID: 18505229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
    Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
    Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ; Slatopolsky E
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
    Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Vitamin D metabolism and current options for therapeutic activation of vitamin D receptor in patients with chronic kidney disease or renal failure].
    Dusilová Sulková S
    Vnitr Lek; 2012 Nov; 58(11):839-49. PubMed ID: 23256830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin D in chronic kidney disease.
    Dusso A; González EA; Martin KJ
    Best Pract Res Clin Endocrinol Metab; 2011 Aug; 25(4):647-55. PubMed ID: 21872805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
    Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
    Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
    Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
    Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
    Zisman AL; Hristova M; Ho LT; Sprague SM
    Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.